Tang Capital Management CLYM Position
Exited4-Fund ConvergenceTang Capital Management exited their position in Climb Bio, Inc. (CLYM) in Q4 2025, after holding the stock for 4 quarters.
The position was first reported in Q1 2025 and has been tracked across 4 quarterly 13F filings.
CLYM is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Budoprutug in 502 days (Aug 31, 2027), making the timing of Tang Capital's position particularly relevant.
Short interest stands at 11.1% of float with 2.7 days to cover, indicating significant bearish positioning against the stock.
About Climb Bio, Inc.
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Full company profile →Short Interest
11.1%
2.7 days to cover
Tang Capital Management CLYM Position History
Frequently Asked Questions
Does Tang Capital Management own CLYM?
No. Tang Capital Management exited their position in Climb Bio, Inc. (CLYM) in Q4 2025. They previously held the stock for 4 quarters.
How many hedge funds own CLYM?
4 specialist biotech hedge funds currently hold CLYM, including RA Capital Management, Deep Track Capital, Boxer Capital and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy CLYM?
Tang Capital Management's position in CLYM was first reported in Q1 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's CLYM position increasing or decreasing?
Tang Capital Management completely exited their CLYM position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CLYMCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →